Net Loss per Common Share	9 Months Ended
Sep. 30, 2023
Net loss per common share
Net Loss per Common Share	Note 5. Net Loss per Common Share Basic loss per share is calculated based upon the net loss available to common stockholders divided by the weighted average number of common shares outstanding during the period. Diluted loss per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects of all dilutive potential common shares outstanding during the period. The dilutive effects of preferred stock, options and warrants and their equivalents are computed using the treasury stock method. The total number of shares of common stock issuable upon exercise of warrants, stock option grants and equity awards was 1,147,960 and 1,346,472 shares for the three-month and nine-month periods ended September 30, 2023 and 2022, respectively. For the three-month and nine-month periods ended September 30, 2023 and 2022, diluted loss per common share was the same as basic loss per common share as the other warrants and equity awards that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted loss per common share as their effect would have been anti-dilutive. The Company did not pay any dividends during the three-month and nine-month periods ended September 30, 2023 and 2022.

Net Loss per Common Share

9 Months Ended

Sep. 30, 2023

Note 5. Net Loss per Common Share

Basic loss per share is calculated based upon the net loss available to common stockholders divided by the weighted average number of common shares outstanding during the period. Diluted loss per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects of all dilutive potential common shares outstanding during the period. The dilutive effects of preferred stock, options and warrants and their equivalents are computed using the treasury stock method.

The total number of shares of common stock issuable upon exercise of warrants, stock option grants and equity awards was 1,147,960 and 1,346,472 shares for the three-month and nine-month periods ended September 30, 2023 and 2022, respectively. For the three-month and nine-month periods ended September 30, 2023 and 2022, diluted loss per common share was the same as basic loss per common share as the other warrants and equity awards that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted loss per common share as their effect would have been anti-dilutive. The Company did not pay any dividends during the three-month and nine-month periods ended September 30, 2023 and 2022.